Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study

NCT02058316

Invasive Pulmonary Aspergillosis

COMPLETED

Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis

NCT02332122

Chronic Obstructive Pulmonary Disease

UNKNOWN

Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis

NCT05064605

Chronic Respiratory Disease Chronic Pulmonary Aspergillosis

UNKNOWN

Outcome After Treatment of Pulmonary Aspergilloma

NCT01958710

Pulmonary Fungal Diseases

UNKNOWN

Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

NCT02104479

Invasive Aspergillosis Pleural Effusion Immunosuppression

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Invasive Pulmonary Aspergillosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Invasive pulmonary aspergillosis (IPA)

Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)

No interventions assigned to this group

Controls

Patients without signs of infection.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hospitalisation in the hematology or intensive care department
* age \> 16 years
* informed consent
* proven or probable IPA (EORTC/ MSG criteria)
* galactomannan positivity in BAL or serum